Drug Trial Radar · NCT00325650
Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: May 18, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2,420
Actual
Start
May 2006
Primary completion
Mar 2009
Study completion Mar 2009
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- May 15, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 35 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary objective: To evaluate the effect of long-term administration of Rimonabant on the time of progression to type 2 diabetes in patients with prediabetes (i.e. Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT) or both at baseline). Secondary objectives: * To assess the effect on weight loss and weight maintenance; sustained effect following a washout period, effect on other markers of glycemic control (fasting glucose, fasting-insulin and HbA1c), glucose tolerance and insulin responses during oral glucose tolerance tests (OGTTs), and on other risk factors (HDL-Cholesterol, TG), * To assess the effect on quality of life * To evaluate long term safety and tolerability.
Conditions
- Prediabetic State
Interventions
RimonabantDrug
Tablet, oral administration
Placebo (for Rimonabant)Drug
Tablet, oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time of progression to type 2 diabetesTime frame: Baseline to 30 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sanofi-Aventis
Bridgewater, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.